AMERICAN BIO MEDICA CORPORATION (OTCMKTS:ABMC) Files An 8-K Submission of Matters to a Vote of Security Holders
ITEM 5.07
|
Submission of Matters to a Vote of Security Holders |
At the Annual Meeting of the Shareholders of the Company held on
June 15, 2017 (the Annual Meeting), at the Companys corporate
offices in Kinderhook, New York, the following matters were voted
upon.
PROPOSAL NUMBER 1 ELECTION OF DIRECTORS
|
Total Shares in Attendance: |
26,032,081 |
Total Shares Outstanding (as of April 27, 2017):29,297,333 |
|||
| Percent of Shares Voted: | 88.85% | ||||
| Director | For | Percent | Withheld | Percent | Broker Non-Vote |
| Jean Neff | 12,595,318 | 94.26 | 766,716 | 5.74 | 12,670,047 |
| Diane J. Generous | 10,328,347 | 77.30 | 3,033,687 | 22.70 | 12,670,047 |
PROPOSAL NUMBER 2 RATIFICATION OF AUDITORS
|
Total Shares in Attendance: |
26,032,081 |
Total Shares Outstanding (as of April 27, 2017):29,297,333 |
||||
| Percent of Shares Voted: | 88.85% | |||||
| For | Percent | Against | Percent | Abstain | Percent | Broker Non-Vote |
| 25,916,242 | 99.55 | 62,219 | 0.24 | 53,620 | 0.21 | |
A description of the proposals can be found in the Companys
definitive proxy statement for the Annual Meeting filed with the
U.S. Securities and Exchange Commission on April 27, 2017.
The nominees for election to the Board of Directors were each
elected for a three-year term ending in 2020, or until their
successor(s) is/are elected and duly qualified. In addition to
the directors elected at the Annual Meeting, Melissa A.
Waterhouse continued her term of office after the Annual Meeting.
There were no other matters voted upon at the Annual Meeting
other than the Proposals noted above.
About AMERICAN BIO MEDICA CORPORATION (OTCMKTS:ABMC)
American Bio Medica Corporation develops, manufactures and sells immunoassay tests, primarily for the immediate, point of collection testing (POCT) for drugs of abuse (DOA) in urine and oral fluids. The Company’s DOA POCT products offer employers, law enforcement, government, healthcare and education professionals to identify illicit drug use. In addition to the manufacture and sale of DOA POCT products, the Company provides bulk test strip manufacturing services to unaffiliated third parties on a contract basis. Its Rapid Drug Screen (RDS) is a POCT product that detects the presence or absence of 2 to 10 DOA simultaneously in a single urine specimen. The Rapid ONE product line consists of single drug tests, each of which tests for the presence or absence of a single drug of abuse in a urine specimen. The RDS InCup is a POCT product that detects the presence or absence of 1 to 12 DOA in a single urine specimen. The POCT products for oral fluid-based DOA testing include OralStat.
